Role of TNFRSF1B polymorphisms in the response of Crohn’s disease patients to infliximab

Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis

“…Genetic test was not available in our study. Genetic polymorphisms may contribute to predict efficacy of infliximab [28,29].…”

The tumor necrosis factor receptor superfamily member 1B polymorphisms predict response to anti-TNF therapy in patients with autoimmune disease: A meta-analysis

“…After the full-text review, 10 of these 18 articles were excluded because 2 of them were review articles [16,24], 3 articles had no exact statistics about polymorphisms [25][26][27], 1 reported duplicate data [28], 1 was irrelevant to biological agent [29], 3 were not related to TNFRSF polymorphisms [2,30,31]. Finally, in the current study, 8 eligible studies [32][33][34][35][36][37][38][39] that meet the inclusion criteria were included in our biologic-specific meta-analysis.…”

“…Therefore, seven of the eight studies containing 929 subjects for TNFRSF1B rs1061622 and five of eight studies involving 564 subjects for TNFRSF1A rs767455 were finally analyzed in our meta-analysis. For TNFRSF1B rs1061622, the subjects in three included studies were of RA [36,38,39], two CD [33,34] and the other two of psoriasis [32,37]. As for TNFRSF1A rs767455, two studies were carried out in RA [35,39], two in CD [33,34] and the other one in psoriasis [35] ( Table 2).…”

“…For TNFRSF1B rs1061622, the subjects in three included studies were of RA [36,38,39], two CD [33,34] and the other two of psoriasis [32,37]. As for TNFRSF1A rs767455, two studies were carried out in RA [35,39], two in CD [33,34] and the other one in psoriasis [35] ( Table 2). Different genotyping methods were utilized including polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP), melting curve-based analysis using LightCycler 480 RealTime PCR System, FRET and big dye chemistry.…”

Considerations, challenges and future of anti-TNF therapy in treating inflammatory bowel disease

“…The best candidates are TNF-α promoter -308 A/G and -857 C/T polymorphisms [119], TNF receptors TNFRSF1A and TNFRSF1B polymorphisms [120,121] and polymorphism in the variable number of tandem repeats in the promotor region of the FcRn gene [122].…”